Leveraging intellectual property as bifunctional protein degraders enter clinical trials

Targeted protein degraders such as proteolysis targeting chimeras (PROTACs) have been a significant development in the therapeutics space. These…

Related Keywords

Michigan ,United States ,Sindhu Vijayakrishnan ,Oerth Bio ,University Of Michigan ,Genentech ,Pfizer ,University Of Dundee ,Global Prior Art Inc ,Dana Farber Cancer Institute ,Patent Cooperation Treaty ,Nature Reviews Clinical Oncology ,Targeted Protein ,Prior Art ,Law ,Lawyers ,Legal ,Aw Firms ,Aw Updates ,Egal Updates ,Egal Developments ,Aw Developments ,Egal Newsletters ,Egal Current Awareness ,Deals ,Egal Advisers ,Egal Advisors ,Egal Directory ,Sa ,Ealthcare Amp Life Sciences ,